Lindsay Berry is a Senior Statistical Scientist at Berry Consultants specializing in the design of Bayesian and adaptive clinical trials. She serves as an elected officer of the Section on Biostatistics and Pharmaceutical Statistics for the International Society for Bayesian Analysis (ISBA). She earned her PhD in Statistical Science from Duke University. During the COVID-19 pandemic, Dr. Berry was heavily involved in the design of Bayesian adaptive platform trials, leading to publication of actionable findings in the Journal of the American Medical Association and the New England Journal of Medicine. Dr. Berry’s interests focus on innovative Bayesian methods for clinical trials including adaptive allocation procedures, historical borrowing, evaluation of heterogeneity of treatment effect, and disease progression modeling.